Table 2.

Laboratory characteristics of the COVID-19 patients and the control patients.

	COVID-19 patients	control patients	t/χ2	P
N	157	93
SpO2 (%)	92.5 ± 15.0	96.21 ± 2.51	16.335	.019
Routine blood test
White-cell count, E+09/L			1.655	.437
≥10	19 (12.1%)	10 (10.8%)
≥4, <10	125 (79.6%)	79 (84.9%)
<4	13 (8.3%)	4 (4.3%)
Lymphocyte count, E+09/L			1.546	.462
≥4	2 (1.3%)	3 (3.2%)
≥0.8, <4	97 (61.8%)	60 (64.5%)
<0.8	58 (36.9%)	30 (32.3%)
Platelet count, E+09/L			5.381	.068
≥300	4 (2.5%)	4 (4.3%)
≥100, <300	112 (71.3%)	76 (81.7%)
<100	41 (26.1%)	13 (14.0%)
Hematocrit (%)			0.457	.499
<40 (male), <35 (female)	98 (62.4%)	62 (66.7%)
40–50 (male),  35–45 (female)	59 (37.6%)	31 (33.3%)
C-reactive protein (mg/L)			9.192	.002
>8	111 (70.7%)	48 (51.6%)
≤8	46 (29.3%)	45 (48.4%)
D-dimer (mg/L)			6.022	.014
>0.55	104 (66.2%)	47 (50.5%)
≤0.55	53 (22.8%)	46 (49.5%)
PT (second)	11.20 ± 1.68	8.23 ± 0.95	3.908	.000
INR	1.00 ± 0.15	0.99 ± 0.20	0.109	.231
Liver function
PA (mg/L)			16.897	.000
<200	128 (83.1%)	56 (59.6%)
≥200	29 (16.9%)	37 (40.4%)
ALB (g/L)			18.406	.000
<35	65 (42.4%)	15 (16.0%)
≥35	92 (57.6%)	78 (84.0%)
TB (umol/L)			2.718	.096
>20.4	53 (34.4%)	23 (24.5%)
≤20.4	104 (65.6%)	70 (75.5%)
ALT (U/L)			21.963	.000
>40	79 (51.3%)	20 (21.3%)
≤40	78 (48.7%)	73 (78.7%)
AST (U/L)			7.803	.005
>40	59 (38.3%)	20 (21.3%)
≤40	98 (61.7%)	73 (78.7%)
LDH (U/L)			9.701	.002
>240	72 (45.5%)	25 (26.6%)
≤240	85 (54.5%)	68 (73.4%)
GGT (U/L)			3.661	.056
>50	61 (39.6%)	26 (27.7%)
≤50	96 (60.4%)	67 (62.3%)
ALP (U/L)			0.008	.929
>128	13 (6.5%)	8 (8.5%)
≤128	144 (93.5%)	85 (91.5%)
CHE (U/L)			0.934	.334
<3700	23 (14.9%)	10 (10.6%)
≥3700	134 (85.1%)	83 (89.4%)